tiprankstipranks

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on RGNX stock, giving a Buy rating yesterday.

Mani Foroohar has given his Buy rating due to a combination of factors that position RegenXBio favorably in the market. The recent safety concerns surrounding a competitor’s product, Elevidys, have highlighted the importance of a strong risk/benefit profile, which RegenXBio appears to possess.
RegenXBio’s use of a different AAV capsid and transgene, along with a clean safety record in their current trials, sets them apart. Additionally, the company’s encouraging efficacy results to date support a positive outlook. These elements combined suggest a promising opportunity for RegenXBio to capture market share, justifying the Buy rating.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.

Disclaimer & DisclosureReport an Issue